TD Cowen reiterates Buy on Baldwin Insurance stock, cites growth potential

TD Cowen reiterated a Buy rating on Baldwin Insurance Group with a $37 price target, implying substantial upside from the current $18.14 share price. The firm sees mid-single-digit organic growth in Q2 2026 accelerating to double digits by Q4 2026, with adjusted EBITDA margins expanding toward 30% over four to five years. The company also reported Q1 2026 revenue of $532.2 million, beating consensus by 1.59%, while EPS of $0.63 matched expectations and $203 million remains on its buyback authorization.

Analysis

The setup is less about a one-quarter beat and more about the market re-rating a compounding story that is still being discounted like a stagnant broker. If organic growth inflects from mid-single digits toward double digits while margins grind up, the operating leverage is meaningful because the market is currently valuing the company closer to a low-quality cyclical than a scalable distribution asset. That creates a path for multiple expansion first, with earnings revisions lagging behind as investors underwrite the durability of cross-sell and embedded-channel economics.

The underappreciated second-order effect is capital allocation: with buybacks as the top priority and the stock trading at a depressed multiple, every dollar of repurchase is more accretive than incremental M&A in the near term. That supports a self-reinforcing floor under EPS even if growth is lumpy, which matters because broker names often get punished on any deceleration. The real catalyst is not the current quarter; it is whether the next two earnings prints can validate that the growth reacceleration is broad-based rather than driven by one-off customer wins.

The main risk is that this remains a "show me" story until the margin bridge is visible in reported numbers. If organic growth stalls in the mid-single digits for longer than expected, the stock likely stays trapped in a value multiple despite cheap headline valuation, because the market will question the quality of the pipeline and the conversion of acquisition-led distribution into recurring cross-sell. Conversely, if guidance begins to reflect sustained double-digit organic growth by late 2026, the current discount to peers looks unusually wide and could close faster than the earnings cycle alone would imply.

Key Decisions for Investors

• Long BWIN into the next 1-2 earnings prints; target a 12-18 month horizon with a 2-3x upside to downside setup if growth reacceleration is confirmed and the multiple normalizes toward peer levels.
• Add via call spreads rather than outright stock if liquidity is acceptable: buy 6-12 month BWIN call spreads to express the re-rating thesis while limiting downside if organic growth disappoints.
• Pair trade: long BWIN / short a higher-multiple retail broker or insurance distribution peer over 6-9 months to isolate valuation convergence from sector beta.
• Use the current depressed multiple as a signal to monitor buyback cadence; if repurchases remain active on weakness, treat dips as entries rather than exits.
• Trim or hedge if the next two quarters do not show sequential improvement in organic growth, because the stock likely needs evidence before it earns a durable rerating.